Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.30 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5692736 | 0.73 | CA1 (0.45) | LMNAALDH1A1HSD17B10POLBHPGD | |
| SCHEMBL5692832 | 0.73 | CA1 (0.48) | LMNAALDH1A1KEAP1HTT | |
| SCHEMBL3393669 | 0.68 | KMT2A (0.34) | — | |
| SCHEMBL2912774 | 0.65 | ALDH1A1 (0.53) | LMNAALDH1A1HSD17B10SMN1; SMN2MAPT | |
| SCHEMBL2915082 | 0.65 | CA1 (0.66) | ALDH1A1HSD17B10HPGD | |
| SCHEMBL12795404 | 0.64 | RAB9A (0.49) | LMNANPC1ABL1ALDH1A1POLB | |
| SCHEMBL11362830 | 0.61 | ALDH1A1 (0.51) | LMNANPC1ALDH1A1HSD17B10POLB | |
| SCHEMBL14707975 | 0.61 | SCN9A (0.39) | LMNANPC1 | |
| SCHEMBL21899349 | 0.60 | CTPS1 (0.50) | ABL1ALDH1A1HSD17B10POLBSMN1; SMN2 | |
| SCHEMBL5058378 | 0.60 | KMT2A (0.46) | LMNANPC1ALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343561-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | claimed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | claimed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | claimed |
| US-7067516-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2006-06-27 | — | — | US | claimed |
| US-20040116439-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2004-06-17 | — | — | US | claimed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | claimed |
| EP-1343561-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-09-17 | — | — | EP | claimed |
| EP-1294691-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-03-26 | — | — | EP | claimed |
| WO-2002047762-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2002-06-20 | — | — | WO | claimed |
| WO-2001096305-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| US-7381734-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| EP-1343561-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | disclosed |
| US-7067516-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-4487927-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0123024-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
| US-4423213-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
| US-4409214-A | Including cefixime; antibiotics | FUJISAWA PHARMACEUTICAL, CO., LTD. (JP) | 1983-10-11 | — | — | US | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216403-A1 | Serine protease inhibitors | SERPINB1, SERPINE1, PRSS1 | LMNA 233/4885NPC1 920/4885ABL1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.